-
Something wrong with this record ?
Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium
P. Kovarikova, I. Pasakova-Vrbatova, A. Vavrova, J. Stariat, J. Klimes, T. Simunek,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Validation Study
- MeSH
- Chromatography, Liquid methods MeSH
- Ethylenediamines pharmacokinetics MeSH
- Glycine analogs & derivatives pharmacokinetics MeSH
- Spectrometry, Mass, Electrospray Ionization methods MeSH
- Myocytes, Cardiac metabolism MeSH
- Cardiovascular Agents pharmacokinetics MeSH
- Rabbits MeSH
- Rats MeSH
- Cells, Cultured MeSH
- Animals, Newborn MeSH
- Pilot Projects MeSH
- Rats, Wistar MeSH
- Razoxane pharmacokinetics MeSH
- Sensitivity and Specificity MeSH
- Tandem Mass Spectrometry methods MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Validation Study MeSH
Dexrazoxane (DEX) is the only clinically used drug effective against anthracycline-induced cardiotoxicity and extravasation injury. However, the mechanism of its cardioprotective action still remains elusive. This paucity of comprehensive data is at least partially caused by the analytical difficulties associated with selective and sensitive simultaneous determination of the parent drug and its putative active metabolite ADR-925 in the relevant biological material. The aim of this study was to develop and validate the first LC-MS/MS method for simultaneous determination of DEX and ADR-925 in the isolated rat neonatal ventricular cardiomyocytes (NVCMs) and the cell culture medium. The analysis was performed on a Synergi Polar-RP column using the gradient profile of the mobile phase composed of 2mM ammonium formate and methanol. Electrospray ionization and ion trap mass analyzer were used as ionization and detection techniques, respectively. NVCMs were precipitated with methanol and the cell culture medium samples were diluted with the same solvent prior the LC-MS/MS analysis. The method was validated within the range of 4-80pmol/10(6) NVCMs and 7-70pmol/10(6) NVCMs for DEX and ADR-925, respectively, and at the concentrations of 8-100μM for both compounds in the culture cell medium. The practical applicability of this method was confirmed by the pilot analysis of NVCMs and the corresponding cell medium samples from relevant in vitro experiment. Hence, the LC-MS/MS method developed in this study represents a modern analytical tool suitable for investigation of DEX bioactivation inside the cardiomyocytes. In addition, the basic utility of the method for the analysis of DEX and ADR-925 in plasma samples was proved in a pilot experiment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031690
- 003
- CZ-PrNML
- 005
- 20131007125803.0
- 007
- ta
- 008
- 131002s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2012.12.024 $2 doi
- 035 __
- $a (PubMed)23339990
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kovarikova, Petra $u Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. petra.kovarikova@faf.cuni.cz
- 245 10
- $a Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium / $c P. Kovarikova, I. Pasakova-Vrbatova, A. Vavrova, J. Stariat, J. Klimes, T. Simunek,
- 520 9_
- $a Dexrazoxane (DEX) is the only clinically used drug effective against anthracycline-induced cardiotoxicity and extravasation injury. However, the mechanism of its cardioprotective action still remains elusive. This paucity of comprehensive data is at least partially caused by the analytical difficulties associated with selective and sensitive simultaneous determination of the parent drug and its putative active metabolite ADR-925 in the relevant biological material. The aim of this study was to develop and validate the first LC-MS/MS method for simultaneous determination of DEX and ADR-925 in the isolated rat neonatal ventricular cardiomyocytes (NVCMs) and the cell culture medium. The analysis was performed on a Synergi Polar-RP column using the gradient profile of the mobile phase composed of 2mM ammonium formate and methanol. Electrospray ionization and ion trap mass analyzer were used as ionization and detection techniques, respectively. NVCMs were precipitated with methanol and the cell culture medium samples were diluted with the same solvent prior the LC-MS/MS analysis. The method was validated within the range of 4-80pmol/10(6) NVCMs and 7-70pmol/10(6) NVCMs for DEX and ADR-925, respectively, and at the concentrations of 8-100μM for both compounds in the culture cell medium. The practical applicability of this method was confirmed by the pilot analysis of NVCMs and the corresponding cell medium samples from relevant in vitro experiment. Hence, the LC-MS/MS method developed in this study represents a modern analytical tool suitable for investigation of DEX bioactivation inside the cardiomyocytes. In addition, the basic utility of the method for the analysis of DEX and ADR-925 in plasma samples was proved in a pilot experiment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a novorozená zvířata $7 D000831
- 650 _2
- $a kardiovaskulární látky $x farmakokinetika $7 D002317
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a chromatografie kapalinová $x metody $7 D002853
- 650 _2
- $a ethylendiaminy $x farmakokinetika $7 D005029
- 650 _2
- $a glycin $x analogy a deriváty $x farmakokinetika $7 D005998
- 650 _2
- $a kardiomyocyty $x metabolismus $7 D032383
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a králíci $7 D011817
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a razoxan $x farmakokinetika $7 D011929
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $x metody $7 D021241
- 650 _2
- $a tandemová hmotnostní spektrometrie $x metody $7 D053719
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Pasakova-Vrbatova, Ivana $u -
- 700 1_
- $a Vavrova, Anna $u -
- 700 1_
- $a Stariat, Jan $u -
- 700 1_
- $a Klimes, Jiri $u -
- 700 1_
- $a Simunek, Tomas $u -
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 76(2013), s. 243-51
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23339990 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131007130323 $b ABA008
- 999 __
- $a ok $b bmc $g 995777 $s 830135
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 76 $d 243-51 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20131002
